Dr Craig Thomas
Craig has extensive expertise in toxicology, discovery research, competitive intelligence and due diligence spanning more than three decades. He began his career at the Marion Merrell Dow research institute where he worked in Cardiovascular and CNS discovery before joining Eli Lilly in 1996 where he focused on increasing the efficiency and predictability of early phase safety assessment. Building on this, he spent two years leading cross-functional due diligence then progressed to lead strategic competitive intelligence for neuroscience, including conducting drug target assessments. Craig is passionate about the critical role toxicology plays in delivering innovative molecules with optimal risk-benefit profiles to address major unmet medical needs.
Read more here Dr Craig Thomas